CN111194786A - Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof - Google Patents
Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof Download PDFInfo
- Publication number
- CN111194786A CN111194786A CN202010134336.2A CN202010134336A CN111194786A CN 111194786 A CN111194786 A CN 111194786A CN 202010134336 A CN202010134336 A CN 202010134336A CN 111194786 A CN111194786 A CN 111194786A
- Authority
- CN
- China
- Prior art keywords
- parts
- codonopsis pilosula
- oligosaccharide
- calcium
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 80
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 80
- 235000013336 milk Nutrition 0.000 title claims abstract description 73
- 239000008267 milk Substances 0.000 title claims abstract description 73
- 210000004080 milk Anatomy 0.000 title claims abstract description 73
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000011575 calcium Substances 0.000 title claims abstract description 55
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 61
- 239000000843 powder Substances 0.000 claims abstract description 50
- 239000006041 probiotic Substances 0.000 claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 claims abstract description 36
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 32
- 230000000529 probiotic effect Effects 0.000 claims abstract description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 241000756943 Codonopsis Species 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 241001052560 Thallis Species 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 8
- 230000008014 freezing Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 229940041514 candida albicans extract Drugs 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 229940073490 sodium glutamate Drugs 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000012138 yeast extract Substances 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 235000014103 egg white Nutrition 0.000 claims description 3
- 210000000969 egg white Anatomy 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 206010006956 Calcium deficiency Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229940069978 calcium supplement Drugs 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 230000008855 peristalsis Effects 0.000 abstract description 2
- 235000013406 prebiotics Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PNXNSVYZNGNYIN-UHFFFAOYSA-N acetic acid;butanoic acid;propanoic acid Chemical compound CC(O)=O.CCC(O)=O.CCCC(O)=O PNXNSVYZNGNYIN-UHFFFAOYSA-N 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/18—Milk in dried and compressed or semi-solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a calcium milk tablet containing codonopsis pilosula oligosaccharide, which is prepared from the following raw materials in parts by weight: 50-250 parts of calcium carbonate, 10-500 parts of codonopsis pilosula oligosaccharide, 300 parts of milk powder, 0-150 parts of probiotic powder, 4-6 parts of magnesium stearate and 10-20 parts of sodium carboxymethylcellulose; and provides a preparation method thereof. The invention has the beneficial effects that: the calcium milk tablet containing the codonopsis pilosula oligosaccharide and the preparation method thereof provided by the invention have no sugar, and the codonopsis pilosula oligosaccharide is used as a main component, so that the calcium milk tablet has the functions of regulating intestinal flora, enhancing the immunity of organisms and the like. The calcium carbonate is added to have the effect of calcium supplement. The codonopsis pilosula oligosaccharide is used as a prebiotic, and the probiotic powder is added, so that the intestinal peristalsis can be promoted, the intestinal health can be improved, and the constipation can be relieved. The prepared radix codonopsitis oligosaccharide calcium milk tablet has unique flavor, is convenient to carry, is widely popular among people, and is particularly suitable for people with low immunity, easy fatigue, frequent constipation and calcium deficiency.
Description
Technical Field
The invention relates to the technical field of food processing, in particular to a calcium milk tablet containing codonopsis pilosula oligosaccharide and a preparation method thereof.
Background
Dangshen is an important edible traditional Chinese medicine, and is good for people with sweet taste from old times, and dangshen oligosaccharide is not only a main sweet component in dangshen, but also has various pharmacological activities of regulating intestinal flora, enhancing immunity, relieving fatigue and the like. The milk tablet is a sheet milk product prepared by taking fresh milk or milk powder as a main raw material and adding a proper amount of auxiliary materials through mixing, tabletting and packaging, and can be carried about without refrigeration and heating for eating.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a calcium milk tablet containing codonopsis pilosula oligosaccharide and a preparation method thereof.
In order to achieve the purpose, the technical scheme provided by the invention is as follows: a calcium milk tablet containing dangshen oligosaccharide is prepared from the following raw materials in parts by weight: 50-250 parts of calcium carbonate, 10-500 parts of codonopsis pilosula oligosaccharide, 300 parts of milk powder, 0-150 parts of probiotic powder, 4-6 parts of magnesium stearate and 10-20 parts of sodium carboxymethylcellulose.
Further, the calcium milk tablet containing the codonopsis pilosula oligosaccharide is prepared from the following raw materials in parts by weight: 150 parts of calcium carbonate, 380 parts of codonopsis pilosula oligosaccharide, 200 parts of milk powder, 50 parts of probiotic powder, 5 parts of magnesium stearate and 15 parts of sodium carboxymethylcellulose.
Further, the preparation method of the codonopsis pilosula oligosaccharide-containing calcium milk tablet comprises the following steps: adding 10, 10 and 10 times of purified water into the coarse powder of the codonopsis pilosula, decocting for 3 times with boiling water, 45 minutes each time, collecting and combining water extract, and concentrating the water extract at 60 ℃ under reduced pressure of 19.9kpa to 1/4 volumes to obtain concentrated solution; adding edible ethanol into the concentrated solution until the final concentration of the ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 60 deg.C under 19.9kpa under reduced pressure until ethanol is volatilized to obtain radix Codonopsis oligosaccharide.
Furthermore, the calcium milk tablet containing the codonopsis pilosula oligosaccharide,the probiotics contained in the probiotic powder are lactobacillus rhamnosus and bifidobacterium lactis; the preparation method of the probiotic powder comprises the following steps: respectively inoculating lactobacillus rhamnosus and bifidobacterium lactis into a culture medium according to the inoculation amount of 1ml/100ml, culturing for 16-24 h at 37 ℃, then centrifuging the bacterium liquid subjected to proliferation culture for 10min at 5000r/min at 3-6 ℃, removing the supernatant, and washing the thalli with equal volume of physiological saline until the thalli are white; resuspending the collected probiotic bacteria with a freeze-drying protective agent, pre-freezing for 2h at-20 ℃, then freezing for 24h at-80 ℃, and placing the bacteria in a freeze dryer for freeze-drying for 13h at-55 ℃ under 5Pa in vacuum; collecting lyophilized powder, and placing in a refrigerator at-70 deg.C for use, wherein the probiotic content is not less than 106CFU/g。
Further, the preparation method of the probiotic inoculation culture medium comprises the following steps: 2% of glucose, 1.5% of dried egg white, 1.5% of yeast extract, 1% of veal extract powder, 0.5% of anhydrous sodium acetate, 0.2% of citric acid and 0.2% of K2HPO4，0.058% MgSO4，0.025% MnSO40.1% of Tween 80, 2% of agar powder, and 6.5-7.0 of PH, and autoclaving at 121 deg.C for 15min to obtain the final product.
Further, the calcium milk tablet containing codonopsis pilosula oligosaccharide comprises the following components in parts by weight: 12 percent of skim milk powder, 2 percent of xylitol, 2.6 percent of sodium acetate and 7.8 percent of sodium glutamate are evenly mixed to obtain the product.
The second purpose of the invention is to provide a preparation method of the calcium milk tablet containing the codonopsis pilosula oligosaccharide, which comprises the steps of firstly uniformly mixing the codonopsis pilosula oligosaccharide, milk powder, probiotic powder and calcium carbonate according to a ratio, sieving by a 60-mesh sieve to obtain a coarse mixture of the codonopsis pilosula oligosaccharide calcium milk tablet, then uniformly mixing magnesium stearate, sodium carboxymethylcellulose and the coarse mixture of the codonopsis pilosula oligosaccharide calcium milk tablet according to a ratio, and then tabletting to obtain the calcium milk tablet containing the codonopsis pilosula oligosaccharide.
The invention has the beneficial effects that: the calcium milk tablet containing the codonopsis pilosula oligosaccharide and the preparation method thereof provided by the invention have no sugar, and the codonopsis pilosula oligosaccharide is used as a main component, so that the calcium milk tablet has the functions of regulating intestinal flora, enhancing the immunity of organisms and the like. The calcium carbonate is added to have the effect of calcium supplement. The codonopsis pilosula oligosaccharide is used as a prebiotic, and the probiotic powder is added, so that the intestinal peristalsis can be promoted, the intestinal health can be improved, and the constipation can be relieved. The prepared radix codonopsitis oligosaccharide calcium milk tablet has unique flavor, is convenient to carry, is widely popular, and is particularly suitable for people with low immunity, frequent constipation and calcium deficiency.
Detailed Description
Example 1:
the calcium milk tablet containing the codonopsis pilosula oligosaccharide is prepared from the following raw materials in parts by weight: 50kg of calcium carbonate, 10kg of codonopsis pilosula oligosaccharide, 100kg of milk powder, 4kg of magnesium stearate and 10kg of sodium carboxymethylcellulose.
The preparation method of the codonopsis pilosula oligosaccharide comprises the following steps: adding 10, 10 and 10 times of purified water into the coarse powder of the codonopsis pilosula, decocting for 3 times in boiling water for 45 minutes each time, collecting and combining water extract, and concentrating the water extract at 60 ℃ under reduced pressure (19.9 kpa) to 1/4 volumes to obtain concentrated solution; adding edible ethanol into the concentrated solution until the final concentration of the ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 60 deg.C under reduced pressure (19.9 kpa) until ethanol is volatilized to obtain radix Codonopsis oligosaccharide.
The probiotics contained in the probiotic powder are lactobacillus rhamnosus and bifidobacterium lactis; the preparation method of the probiotic powder comprises the following steps: respectively inoculating lactobacillus rhamnosus and bifidobacterium lactis into a culture medium according to the inoculation amount of 1ml/100ml, culturing for 16-24 h at 37 ℃, then centrifuging the bacterium liquid subjected to proliferation culture for 10min at 5000r/min at 3-6 ℃, removing the supernatant, and washing the thalli with equal volume of physiological saline until the thalli are white; resuspending the collected probiotic bacteria with a freeze-drying protective agent, pre-freezing for 2h at-20 ℃, then freezing for 24h at-80 ℃, and placing the bacteria in a freeze dryer for freeze-drying for 13h at-55 ℃ under 5Pa in vacuum; collecting the lyophilized powder, and placing in a refrigerator at-70 deg.C for use. Wherein the probiotic amount is more than or equal to 106CFU/g。
The preparation method of the probiotic inoculation culture medium comprises the following steps: 2% of glucose, 1.5% of dried egg white, 1.5% of yeast extract, 1% of veal extract powder, 0.5% of anhydrous sodium acetate, 0.2% of citric acid and 0.2% of K2HPO4，0.058% MgSO4，0.025% MnSO40.1% of Tween 80, 2% of agar powder, and 6.5-7.0 of PH, and autoclaving at 121 deg.C for 15min to obtain the final product.
Wherein the components of the freeze-drying protective agent are as follows: 12 percent of skim milk powder, 2 percent of xylitol, 2.6 percent of sodium acetate and 7.8 percent of sodium glutamate are evenly mixed to obtain the product.
The preparation method of the calcium milk tablet containing the codonopsis pilosula oligosaccharide comprises the steps of firstly uniformly mixing the codonopsis pilosula oligosaccharide, milk powder, probiotic powder and calcium carbonate according to the proportion, sieving by a 60-mesh sieve to obtain a crude mixture of the codonopsis pilosula oligosaccharide calcium milk tablet, then uniformly mixing magnesium stearate, sodium carboxymethylcellulose and the crude mixture of the codonopsis oligosaccharide calcium milk tablet according to the proportion, and then tabletting to obtain the calcium milk tablet containing the codonopsis pilosula oligosaccharide.
Example 2:
the calcium milk tablet containing the codonopsis pilosula oligosaccharide is prepared from the following raw materials in parts by weight: 250kg of calcium carbonate, 500kg of codonopsis pilosula oligosaccharide, 300kg of milk powder, 150kg of probiotic powder, 6kg of magnesium stearate and 20kg of sodium carboxymethylcellulose.
Methods for preparing codonopsis pilosula oligosaccharide, probiotic powder and calcium milk tablets containing codonopsis pilosula oligosaccharide are the same as in example 1.
Example 3:
the calcium milk tablet containing the codonopsis pilosula oligosaccharide is prepared from the following raw materials in parts by weight: 150kg of calcium carbonate, 380kg of codonopsis pilosula oligosaccharide, 400kg of milk powder, 50kg of probiotic powder, 5kg of magnesium stearate and 15kg of sodium carboxymethylcellulose.
Methods for preparing codonopsis pilosula oligosaccharide, probiotic powder and calcium milk tablets containing codonopsis pilosula oligosaccharide are the same as in example 1.
Example 4:
calcium milk tablet containing dangshen oligosaccharide comprises the following raw materials: 1.5kg of calcium carbonate, 4.0kg of codonopsis pilosula oligosaccharide, 2.5kg of milk powder, 0.5kg of probiotic powder, 40g of magnesium stearate and 100g of sodium carboxymethylcellulose.
Inoculating probiotics into a carrot culture medium containing 1.5% of peptone, 1.5% of yeast extract powder and 0.8% of calcium carbonate, culturing for 18h at 37 ℃, centrifuging the bacterium liquid subjected to proliferation culture for 10min at 5 ℃ at 5000r/min, removing supernatant, and washing the thalli with equal volume of physiological saline until the thalli are white; resuspending the collected probiotic bacteria by using a freeze-drying protective agent containing 12% of skimmed milk powder, 2% of xylitol, 2.6% of sodium acetate and 7.8% of sodium glutamate, pre-freezing for 2h at-20 ℃, then freezing for 24h at-80 ℃, and placing the bacteria in a freeze dryer for freeze-drying for 13h at-55 ℃ under 5Pa vacuum; collecting lyophilized powder, and placing in a refrigerator at-70 deg.C;
radix codonopsis oligosaccharide calcium milk tablet mixture: uniformly mixing 1.5kg of calcium carbonate, 4.0kg of codonopsis pilosula oligosaccharide, 2.5kg of milk powder and 0.5kg of probiotic powder, and sieving by using a 60-mesh sieve to obtain a crude mixture of codonopsis pilosula oligosaccharide calcium milk tablets;
and (3) uniformly mixing 40g of magnesium stearate, 100g of sodium carboxymethylcellulose and the crude mixture of the codonopsis pilosula oligosaccharide calcium milk tablets, and tabletting to obtain the codonopsis oligosaccharide calcium milk tablets.
Example 5:
immunoregulation and intestinal flora regulation effects of dangshen oligosaccharide calcium milk tablet on rats with spleen deficiency syndrome
(1) Establishing a model: SD rats were randomly aliquoted into 3 groups: blank control group, spleen deficiency model group, radix Codonopsis oligosaccharide calcium milk tablet group 10 each. A rat spleen deficiency model is replicated by adopting a three-factor composite method: a. rheum officinale (200%, dosage 20 g/kg); b. swimming until exhaustion (the nose tip is submerged in the water for 5 s), and swimming every other day; c. fasting every other day, and molding 21 d. After the molding is finished, the radix codonopsitis oligosaccharide calcium milk tablet is fed into the radix codonopsitis oligosaccharide calcium milk tablet group, and distilled water is fed into the gavage of the blank control group and the model control group, wherein the feeding volume is 20mL/kg, and the feeding is continuously carried out for 7 days.
(2) General state observation: after the spleen deficiency model is copied by adopting a three-factor composite method, compared with a blank control group, animals in the model group gradually have symptoms of loose stool, anus filthy, emaciation, gradually reduced activity, dry and lusterless hair and the like. After administration, the feces of each treatment group gradually became thick to dry, the activity increased, and the hair became fluffy and glossy and close to that of the blank control group.
(3) And (3) detecting immune function: before the experiment, rats in each group were fasted and treated with water for 12 hours, and indian ink diluted to a stock solution concentration of 1/4 was injected into each rat by tail vein injection. After injection of India ink, the time was started and 20 μ of blood was drawn from the venous plexus of the rat's canthus at time points 2 min and 10min by capillaryL, placed in an anticoagulation tube and immediately added to 2 mL of pre-prepared Na2CO3(0.1%) in solution. With an equal volume of Na2CO3The solution was used as a blank, absorbance value was measured at 600nm wavelength (A600 nm). the rat was sacrificed and the liver and spleen were taken out under aseptic conditions, blood stain on the organs was blotted with filter paper and excess components were removed, and weighing was performed.the size of phagocytic index α represents the degree of clearance of carbon particles in the rat, and the larger the α value, the stronger the phagocytic ability, the calculation formula of phagocytic index α is as follows:
K=（lgOD1- lgOD2）/（t2-t1）
phagocytic index α = K( 1/3)X body weight/(liver weight + spleen weight)
Experimental results show that the phagocytic index α of the rat in the model group is remarkably reduced (P is less than 0.01) compared with the normal group, the phagocytic index of the rat treated by CTX (α) can be effectively increased by the codonopsis pilosula oligosaccharide milk tablet group compared with the model group, and the experimental results show that CPO can enhance the carbon clearance capacity of the rat with spleen deficiency syndrome, and the codonopsis pilosula oligosaccharide calcium milk tablet has immunoregulatory activity.
Table 1 shows the effect of Codonopsis pilosula oligosaccharide on immunoregulatory activity of rats with spleen deficiency syndrome.
TABLE 1
| Phagocytic index | |
| Blank group | 10.08±3.46 |
| Control group | 6.56±2.22# |
| Radix codonopsis oligosaccharide calcium milk tablet set | 9.06±2.44* |
Note: in comparison with the blank set, the results,#P<0.05; in comparison with the set of models,*P<0.05。
(3) influence of the content of short-chain fatty acids in the codonopsis pilosula oligosaccharide calcium milk tablets: fresh rat feces are collected after the experiment is finished, the feces are placed in a sterile centrifuge tube, and the samples are immediately frozen and stored at-80 ℃ for later use after being collected. Taking 2.0 g of a fecal sample, adding 10 mL of water, performing vortex crushing, uniformly mixing, and performing 5000r min-1Centrifuging for 20 min, collecting supernatant 2.0 mL, adding 50% H2SO40.2 mL, and adding diluted internal standard solution (taking 50 mL of internal standard solution, adding ether for dilution, and measuring the content of acetic acid, propionic acid and butyrate by using a gas chromatography method.
The feces of the rats in each group were analyzed, and the content changes of acetic acid, propionic acid and butyric acid are shown in Table 2. The result shows that compared with a blank group, the 3 detection indexes of the rats in the model group are obviously reduced; compared with a model group, the 3 indexes of the radix codonopsitis oligosaccharide calcium milk tablet group are obviously increased. The codonopsis pilosula oligosaccharide calcium milk tablet has the function of regulating intestinal flora.
Table 2 shows the effect of dangshen oligosaccharide calcium milk tablets on the content of short-chain fatty acids in rats with spleen deficiency syndrome.
TABLE 2
| Acetic acid | Propionic acid | Butyric acid | |
| Blank group | 0. 63 ± 0. 05 | 0. 62 ± 0. 09 | 1. 64 ± 0. 38 |
| Model set | 0. 42 ± 0. 10# | 0. 39 ± 0. 08## | 0. 70 ± 0. 14## |
| Radix codonopsis oligosaccharide calcium milk tablet set | 0. 58 ± 0. 08* | 0. 52 ± 0. 06** | 1. 23 ± 0. 23** |
Note: in comparison with the blank set, the results,#P<0.05，##P<0.05; in comparison with the set of models,*P<0.05，**P<0.05。
finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The calcium milk tablet containing codonopsis pilosula oligosaccharide is characterized by being prepared from the following raw materials in parts by weight: 50-250 parts of calcium carbonate, 10-500 parts of codonopsis pilosula oligosaccharide, 300 parts of milk powder, 0-150 parts of probiotic powder, 4-6 parts of magnesium stearate and 10-20 parts of sodium carboxymethylcellulose.
2. The calcium milk tablet containing codonopsis pilosula oligosaccharide according to claim 1 is prepared from the following raw materials in parts by weight: 150 parts of calcium carbonate, 380 parts of codonopsis pilosula oligosaccharide, 200 parts of milk powder, 50 parts of probiotic powder, 5 parts of magnesium stearate and 15 parts of sodium carboxymethylcellulose.
3. The calcium milk tablet containing codonopsis pilosula oligosaccharides according to claim 1 or 2, wherein the preparation method of the codonopsis pilosula oligosaccharides comprises the following steps: adding 10, 10 and 10 times of purified water into the coarse powder of the codonopsis pilosula, decocting for 3 times with boiling water, 45 minutes each time, collecting and combining water extract, and concentrating the water extract at 60 ℃ under reduced pressure of 19.9kpa to 1/4 volumes to obtain concentrated solution; adding edible ethanol into the concentrated solution until the final concentration of the ethanol is 80%, precipitating with ethanol, and collecting supernatant; concentrating the supernatant at 60 deg.C under 19.9kpa under reduced pressure until ethanol is volatilized to obtain radix Codonopsis oligosaccharide.
4. The calcium milk tablet containing codonopsis pilosula oligosaccharides according to claim 1 or 2, wherein the probiotics contained in the probiotic powder are lactobacillus rhamnosus and bifidobacterium lactis; the preparation method of the probiotic powder comprises the following steps: respectively inoculating lactobacillus rhamnosus and bifidobacterium lactis into a culture medium according to the inoculation amount of 1ml/100ml, culturing for 16-24 h at 37 ℃, then centrifuging the bacterium liquid subjected to proliferation culture for 10min at 5000r/min at 3-6 ℃, removing the supernatant, and washing the thalli with equal volume of physiological saline until the thalli are white; resuspending the collected probiotic bacteria with a freeze-drying protective agent, pre-freezing for 2h at-20 ℃, then freezing for 24h at-80 ℃, and placing the bacteria in a freeze dryer for freeze-drying for 13h at-55 ℃ under 5Pa in vacuum; collecting lyophilized powder, and placing in a refrigerator at-70 deg.C for use, wherein the probiotic content is not less than 106CFU/g。
5. The calcium milk tablet containing codonopsis pilosula oligosaccharide according to claim 4, wherein the probiotic inoculation culture medium is preparedThe method comprises the following steps: 2% of glucose, 1.5% of dried egg white, 1.5% of yeast extract, 1% of veal extract powder, 0.5% of anhydrous sodium acetate, 0.2% of citric acid and 0.2% of K2HPO4，0.058% MgSO4，0.025% MnSO40.1% of Tween 80, 2% of agar powder, and 6.5-7.0 of PH, and autoclaving at 121 deg.C for 15min to obtain the final product.
6. The calcium milk tablet containing codonopsis pilosula oligosaccharide according to claim 4, wherein the freeze-drying protective agent comprises the following components: 12 percent of skim milk powder, 2 percent of xylitol, 2.6 percent of sodium acetate and 7.8 percent of sodium glutamate are evenly mixed to obtain the product.
7. The preparation method of the calcium milk tablet containing the codonopsis pilosula oligosaccharide according to any one of claims 1 to 6, characterized in that the codonopsis pilosula oligosaccharide, the milk powder, the probiotic powder and the calcium carbonate are uniformly mixed according to the proportion, and are sieved by a 60-mesh sieve to obtain a crude mixture of the codonopsis pilosula oligosaccharide calcium milk tablet, and then the magnesium stearate, the sodium carboxymethyl cellulose and the crude mixture of the codonopsis pilosula oligosaccharide calcium milk tablet are uniformly mixed according to the proportion, and are tableted to obtain the calcium milk tablet containing the codonopsis oligosaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010134336.2A CN111194786A (en) | 2020-03-02 | 2020-03-02 | Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010134336.2A CN111194786A (en) | 2020-03-02 | 2020-03-02 | Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111194786A true CN111194786A (en) | 2020-05-26 |
Family
ID=70742587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010134336.2A Pending CN111194786A (en) | 2020-03-02 | 2020-03-02 | Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111194786A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777917A (en) * | 2022-10-17 | 2023-03-14 | 甘肃九州天润中药产业有限公司 | Codonopsis pilosula and black sesame instant food and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102754690A (en) * | 2012-07-10 | 2012-10-31 | 陕西农产品加工技术研究院 | Synbiotics goat milk slices and method for preparing same |
| CN103651804A (en) * | 2013-12-18 | 2014-03-26 | 南昌大学 | Prebiotic and probiotic added milk tablet based on homology of medicine and food |
| CN103918793A (en) * | 2014-04-10 | 2014-07-16 | 陕西科技大学 | Stomach-invigorating and digestion-helping probiotics goat milk tablet and preparation method thereof |
| CN105901150A (en) * | 2016-03-31 | 2016-08-31 | 郎法文 | Donkey-hide gelatin-calcium-milk tablet and preparation method thereof |
| CN109730154A (en) * | 2019-01-11 | 2019-05-10 | 东阿阿胶股份有限公司 | A kind of probiotics donkey milk piece and preparation method thereof |
| CN110025622A (en) * | 2019-04-25 | 2019-07-19 | 兰州大学 | A kind of isolation and purification method of Radix Codonopsis oligosaccharides and application |
| CN110115292A (en) * | 2019-06-11 | 2019-08-13 | 河北农业大学 | A kind of probiotic milk tablets and preparation method thereof of pre- anti-caries |
-
2020
- 2020-03-02 CN CN202010134336.2A patent/CN111194786A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102754690A (en) * | 2012-07-10 | 2012-10-31 | 陕西农产品加工技术研究院 | Synbiotics goat milk slices and method for preparing same |
| CN103651804A (en) * | 2013-12-18 | 2014-03-26 | 南昌大学 | Prebiotic and probiotic added milk tablet based on homology of medicine and food |
| CN103918793A (en) * | 2014-04-10 | 2014-07-16 | 陕西科技大学 | Stomach-invigorating and digestion-helping probiotics goat milk tablet and preparation method thereof |
| CN105901150A (en) * | 2016-03-31 | 2016-08-31 | 郎法文 | Donkey-hide gelatin-calcium-milk tablet and preparation method thereof |
| CN109730154A (en) * | 2019-01-11 | 2019-05-10 | 东阿阿胶股份有限公司 | A kind of probiotics donkey milk piece and preparation method thereof |
| CN110025622A (en) * | 2019-04-25 | 2019-07-19 | 兰州大学 | A kind of isolation and purification method of Radix Codonopsis oligosaccharides and application |
| CN110115292A (en) * | 2019-06-11 | 2019-08-13 | 河北农业大学 | A kind of probiotic milk tablets and preparation method thereof of pre- anti-caries |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777917A (en) * | 2022-10-17 | 2023-03-14 | 甘肃九州天润中药产业有限公司 | Codonopsis pilosula and black sesame instant food and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108208853B (en) | Probiotic oligopeptide compound preparation for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| EP1279727B1 (en) | Process for producing preparations of natural medicines | |
| CN113197249B (en) | Yoghurt comprising lactobacillus paracasei Lc19 and preparation method and application thereof | |
| CN110835614B (en) | Bifidobacterium lactis GKK2, composition containing same and application of composition in improving allergic asthma | |
| CN112375713B (en) | Lactobacillus longus SF-B-27 and application thereof | |
| CN107549817B (en) | Moringa oleifera natural organic calcium and preparation method thereof | |
| CN114848685A (en) | Antiallergic probiotic composition, application thereof and probiotic traditional Chinese medicine fermentation product | |
| CN114521590A (en) | White kidney bean probiotic lipid-reducing tablet for blocking absorption of sugar and oil and preparation method thereof | |
| CN111194786A (en) | Calcium milk tablet containing dangshen oligosaccharide and preparation method thereof | |
| CN113755370B (en) | Application of lactobacillus acidophilus LA85 in preparation of hypolipidemic drugs or health-care foods | |
| KR101468698B1 (en) | Development of composition for improving Intestinal Microflora by using three steps fermentation | |
| CN114437997B (en) | Lactobacillus plantarum SF-L38 and application thereof in preparation of blood sugar control product | |
| CN105998222A (en) | Probiotic fermented unprocessed common monkshood daughter root composition and preparation method and application thereof | |
| CN115747121A (en) | Bifidobacterium lactis HSLA-009, microbial inoculum and preparation method and application thereof | |
| CN114451562A (en) | Hovenia dulcis, radix puerariae and corn oligopeptide composition, beverage and preparation method thereof | |
| CN113243532A (en) | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof | |
| CN116240152B (en) | Lactobacillus rhamnosus SF-L30 and application thereof in preparation of lung-heat clearing and inflammation diminishing products | |
| CN116251162B (en) | Traditional Chinese medicine composition for treating abdominal pain and diarrhea, preparation and traditional Chinese medicine plaster | |
| CN116019845B (en) | Pleurotus eryngii extract rich in polysaccharide and application thereof in preparation of products for regulating intestinal flora and relaxing bowels | |
| CN115606727B (en) | Microecological preparation compounded by functional sugar and sheep whey protein, preparation method and application | |
| CN117099850B (en) | Fermented plant-based yoghurt and preparation method and application thereof | |
| CN116686987A (en) | Synbiotic health food containing green tea polyphenols extract and its preparation method | |
| CN112294936A (en) | Culture medium for preparing stomach-protecting fermentation product and preparation method | |
| CN117384979A (en) | Millettia speciosa protein fermentation liquor, preparation method and application thereof in uric acid reduction | |
| CN110801020A (en) | Prebiotics polypeptide composite probiotics for relieving gastrointestinal discomfort and abdominal distension and diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200526 |
|
| RJ01 | Rejection of invention patent application after publication |